.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
QuintilesIMS
Federal Trade Commission
Express Scripts
US Department of Justice
Boehringer Ingelheim
McKesson
Chubb
Dow
Cerilliant

Generated: June 22, 2017

DrugPatentWatch Database Preview

ALTABAX Drug Profile

« Back to Dashboard

What is the patent landscape for Altabax, and when can generic versions of Altabax launch?

Altabax is a drug marketed by Aqua Pharms Llc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-three patent family members in thirty-five countries.

The generic ingredient in ALTABAX is retapamulin. Three suppliers are listed for this compound. Additional details are available on the retapamulin profile page.

Summary for Tradename: ALTABAX

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list34
Clinical Trials: see list5
Patent Applications: see list199
Drug Prices:see details
DailyMed Link:ALTABAX at DailyMed

Pharmacology for Tradename: ALTABAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aqua Pharms Llc
ALTABAX
retapamulin
OINTMENT;TOPICAL022055-001Apr 12, 2007RXYesYes7,875,630► SubscribeY ► Subscribe
Aqua Pharms Llc
ALTABAX
retapamulin
OINTMENT;TOPICAL022055-001Apr 12, 2007RXYesYes8,207,191► Subscribe ► Subscribe
Aqua Pharms Llc
ALTABAX
retapamulin
OINTMENT;TOPICAL022055-001Apr 12, 2007RXYesYesRE43390► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ALTABAX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,281,226 Pleuromutilin derivatives as antimicrobials► Subscribe
RE39128Pleuromutilin derivatives as antimicrobials► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALTABAX

Country Document Number Estimated Expiration
Japan2012020998► Subscribe
Canada2307551► Subscribe
Portugal1930330► Subscribe
World Intellectual Property Organization (WIPO)2005023257► Subscribe
European Patent Office1452534► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALTABAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C042/2007Ireland► SubscribeSPC042/2007: 20080415, EXPIRES: 20220523
2007 00052Denmark► Subscribe
6Finland► Subscribe
1028961/01Switzerland► SubscribePRODUCT NAME: RETAPAMULIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58641 04.08.2009
C/GB07/061United Kingdom► SubscribePRODUCT NAME: RETAPAMULIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/390/001 20070524; UK EU/1/07/390/002 20070524; UK EU/1/07/390/003 20070524; UK EU/1/07/390/004 20070524
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Fuji
Daiichi Sankyo
Dow
Express Scripts
US Department of Justice
Medtronic
Covington
Baxter
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot